Qualigen
QLGN

股本结构

单位：万股
公告日期 2025-11-14 2025-11-14 2025-10-20 2025-09-16 2025-08-14 2025-08-14
证券总股本 516.04 305.68 169.55 169.56 169.55 163.55
普通股本 516.04 305.68 169.55 169.56 169.55 163.55
优先股 未披露 4.50 未披露 未披露 未披露 0.30
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2025-11-14 2025-09-30 2025-09-22 2025-09-12 2025-08-14 2025-06-30
注释：中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本（万股） 变动后优先股（万股） 变动原因 变动日期
2025-11-14 516.04 未披露 定期报告 2025-11-14
2025-11-14 305.68 4.50
更多>>
From June 30, 2025 to September 30, 2025 Issuance of common stock for the conversion of Series A-2 preferred shares Issuance of Series A-3 preferred shares upon closing of private placement Issuance of Series B preferred shares upon closing of private placement Issuance of common stock and warrants upon closing of private placement
2025-09-30
2025-10-20 169.55 未披露 定期报告 2025-09-22
2025-09-16 169.56 未披露 定期报告 2025-09-12
2025-08-14 169.55 未披露 定期报告 2025-08-14
2025-08-14 163.55 0.30
更多>>
From March 31, 2025 to June 30, 2025 Issuance of common stock for the conversion of Series A-2 preferred shares
2025-06-30
2025-06-30 163.55 未披露 定期报告 2025-05-22
2025-07-21 162.53 0.30
更多>>
From December 31, 2024 to March 31, 2025 Issuance of common stock for the conversion of Series A-2 preferred shares
2025-03-31
2025-06-30 73.64 0.63
更多>>
From December 31, 2023 to December 31, 2024 Issuance of common stock and prefunded warrants in public offering Voluntary conversion of convertible debt into common stock Redemptions of convertible debt into common stock Stock issued upon partial exercise of warrants Restricted share settlements issued to former board members Issuance of rounded shares as a result of the reverse stock split
2024-12-31
2024-11-14 73.64 未披露 定期报告 2024-11-12
2024-11-01 73.70 未披露
更多>>
a 1-for-50 reverse stock split of the issued shares of its common stock
2024-11-05
2024-11-01 3670.00 未披露 定期报告 2024-11-01
2024-09-06 2702.20 未披露
更多>>
Common Stock offered 14,724,058 shares by the company
2024-09-06
2024-09-06 1229.80 未披露 定期报告 2024-09-04
2024-09-10 1229.80 未披露 定期报告 2024-08-31
2024-08-07 1215.58 未披露 定期报告 2024-08-06
2024-07-11 1138.28 未披露 定期报告 2024-07-05
2024-07-02 961.39 未披露 定期报告 2024-06-24
2024-05-06 679.08 未披露 定期报告 2024-04-22
2024-07-02 650.07 未披露
更多>>
From December 31, 2023 to March 31, 2024 Monthly redemptions of convertible debt into common stock
2024-03-31
2024-04-08 630.74 未披露 定期报告 2024-03-25
2024-04-08 536.21 未披露
更多>>
From December 31, 2022 to December 31, 2023 Redemptions of convertible debt into common stock Voluntary conversion of convertible debt into common stock
2023-12-31
2023-11-14 518.11 未披露 定期报告 2023-11-10
2023-06-13 505.25 未披露 定期报告 2023-06-12
2023-05-15 505.25 未披露
更多>>
From December 31, 2022 to March 31, 2023 Voluntary conversion of convertible debt into common stock
2023-03-31
2022-12-30 421.07 未披露 定期报告 2022-12-30
2022-11-22 421.10 未披露
更多>>
Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split.
2022-11-23
2022-11-14 4211.02 未披露
更多>>
From June 30, 2022 to September 30, 2022 Stock issued upon exercise of warrants
2022-09-30
2022-06-17 3879.55 未披露 定期报告 2022-06-15
2022-03-31 3529.55 未披露 定期报告 2022-03-25
2022-03-31 3529.02 未披露
更多>>
From December 31, 2020 to December 31, 2021 Issuance of common stock for conversion of preferred stock Stock issued upon cash-exercise of warrants Stock issued upon net-exercise of warrants Shares issued pursuant to Securities Purchase Agreements Stock issued for professional services
2021-12-31
2021-12-01 2940.75 未披露 定期报告 2021-11-30
2021-11-15 2911.71 未披露 定期报告 2021-11-11
2021-11-15 2908.21 0.02
更多>>
From June 30, 2021 to September 30, 2021 Stock issued upon cash-exercise of warrants
2021-09-30
2021-08-16 2899.88 未披露 定期报告 2021-08-12
2021-08-16 2890.22 0.02
更多>>
From March 31, 2021 to June 30, 2021 Stock issued upon cash-exercise of warrants
2021-06-30
2021-05-14 2883.31 0.02
更多>>
From December 31, 2020 To March 31, 2021 Stock issued upon cash-exercise of warrants Stock issued upon net-exercise of warrants Stock issued for professional services
2021-03-31
2021-03-31 2878.07 未披露 定期报告 2021-03-15
2021-03-31 2729.61 0.02
更多>>
From March 31, 2020 to December 31, 2020 Issuance of common stock for conversion of preferred stock Issuance of common stock for conversion of notes payable and accrued interest Effect of reverse recapitalization Shares and warrants issued to advisor upon closing of private placement Shares and warrants issued pursuant to Securities Purchase Agreements Stock issued for professional services Warrants exercised
2020-12-31
2020-12-18 2670.70 未披露
更多>>
1.Common Stock offered by the company: 2,370,786 shares of common stock. 2.The number of shares of common stock to be outstanding immediately after this offering is based on 24,336,263 shares of common stock outstanding as of December 15, 2020.
2020-12-18
2020-12-18 2433.63 0.02 定期报告 2020-12-15
2020-11-12 2306.09 未披露 定期报告 2020-11-05
2020-11-12 2252.99 0.07
更多>>
From June 30, 2020 to September 30, 2020 Issuance of common stock for conversion of preferred stock Shares and (exercised) warrants issued pursuant to Securities Purchase Agreements
2020-09-30
2020-08-04 2102.88 未披露
更多>>
1.Common Stock offered by the company 1,717,106 shares of common stock. 2.The number of shares of common stock to be outstanding immediately after this offering is based on 19,311,731 shares of common stock outstanding as of July 31, 2020.
2020-08-04
2020-08-04 1931.17 0.18 定期报告 2020-07-31
2020-07-10 1682.98 未披露
更多>>
1.Common Stock offered by the company 1,140,570 shares of common stock. 2.The number of shares of common stock to be outstanding immediately after this offering is based on 15,689,223 shares of common stock outstanding as of July 9, 2020.
2020-07-10
2020-07-09 1568.92 0.31 定期报告 2020-07-09
2020-08-14 1358.83 0.46
更多>>
From March 31, 2020 to June 30, 2020 Issuance of common stock for conversion of preferred stock Issuance of Series Alpha preferred shares upon closing of private placement Issuance of Series Alpha preferred stock for conversion of notes payable Issuance of common stock for conversion of notes payable and accrued interest Effect of reverse recapitalization Shares and warrants issued to advisor upon closing of private placement Stock issued for professional services
2020-06-30
2020-05-26 184.61 未披露
更多>>
1-for-25 reverse split
2020-05-26
2020-05-01 4615.30 未披露 定期报告 2020-04-27
2020-04-24 4615.30 未披露 定期报告 2020-04-10
2020-05-01 4571.39 0.02
更多>>
From December 31, 2019 to March 31, 2020 Conversion of Series B preferred shares into common stock Issuance of common shares from ATM Agreement Issuance of common shares from exercises of warrants Proceeds from issuance of shares for Aspire equity line Issuance of shares for settlement of accounts payable
2020-03-31
2020-03-27 4571.39 未披露 定期报告 2020-03-26
2020-03-31 4571.39 未披露 定期报告 2020-03-25
2020-03-13 3922.27 0.02 定期报告 2020-03-05
2020-02-04 3266.50 未披露 定期报告 2020-01-28
2020-03-31 1910.83 0.21
更多>>
From December 31, 2018 to December 31, 2019 Conversion of Series A preferred shares into common stock Conversion of Series B preferred shares into common stock Conversion of Series C preferred shares into common stock Settlement of RSUs Issuance of common shares from ATM Agreement Shareholders fractional adjustment
2019-12-31
2019-11-14 1016.48 未披露 定期报告 2019-11-07
2019-11-14 992.70 0.62
更多>>
From June 30, 2019 to September 30, 2019 Conversion of Series B preferred shares into common stock
2019-09-30
2019-08-14 942.70 未披露 定期报告 2019-08-07
2019-07-24 935.00 未披露 定期报告 2019-07-23
2019-08-14 904.23 0.73
更多>>
From December 31, 2018 to June 30, 2019 Conversion of Series B preferred shares into common stock Conversion of Series C preferred shares into common stock
2019-06-30
2019-05-15 904.23 未披露 定期报告 2019-05-10
2019-05-15 904.23 0.73
更多>>
from December 31, 2018 to March 31, 2019 Conversion of Series B preferred shares into common stock Conversion of Series C preferred shares into common stock
2019-03-31
2019-04-01 904.23 未披露 定期报告 2019-03-10
2019-04-01 603.66 1.16
更多>>
from December 31, 2017 to December 31, 2018 Issuance of Series B preferred shares upon closing of private placement Deemed dividend of preferred stock Conversion of Series A preferred shares into common stock Conversion of Series B preferred shares into common stock
2018-12-31
2018-11-09 573.46 0.60 定期报告 2018-09-30
2018-08-14 553.46 未披露 定期报告 2018-08-10
2018-08-14 533.46 0.76 定期报告 2018-06-30
2018-05-15 501.96 未披露 定期报告 2018-05-11
2018-05-15 501.96 未披露 定期报告 2018-05-07
2018-05-15 502.07 0.88 定期报告 2018-03-31
2018-03-22 494.07 未披露
更多>>
Ritter Pharmaceuticals, Inc. today announced a 1-for-10 reverse split of its Common Stock, effective March 23, 2018.As a result of the reverse stock split, the number of issued and outstanding shares of Common Stock will be reduced from approximately 49,406,521 to approximately 4,940,652.
2018-03-23
2018-03-19 4940.65 0.91
更多>>
from December 31, 2016 to December 31, 2017 Conversion of series A preferred shares Issuance of shares upon follow-on offering Issuance of shares under common stock purchase agreement
2017-12-31
2017-10-31 4950.65 未披露 定期报告 2017-10-27
2017-08-07 1475.65 未披露 定期报告 2017-06-30
2017-05-09 1461.92 未披露 定期报告 2017-05-05
2017-02-27 1161.92 未披露
更多>>
From December 31, 2015 to December 09, 2016 Issuance of common stock upon closing of follow-on public offering Issuance of common stock under common stock purchase agreement Exercise of options on common stock
2016-12-09
2016-11-07 1073.04 未披露
更多>>
On October 31, 2016, the Company closed a public offering, selling 2,127,660 shares of the Company’s common stock at a price to the public of $2.35 per share, for aggregate gross proceeds to the Company of approximately $5.0 million. The Company paid to the underwriters underwriting discounts and commissions of approximately $0.4 million in connection with the offering, and approximately $0.2 million of other expenses in connection with the offering.
2016-11-01
2016-11-07 859.29 未披露 定期报告 2016-09-30
2016-05-09 858.47 未披露 定期报告 2016-03-31
2016-03-21 858.47 未披露 定期报告 2016-03-16
2016-03-21 858.20 未披露
更多>>
from December 31, 2014 to December 31, 2015 Conversion of all outstanding preferred stock subject to redemption to common stock Conversion of all outstanding preferred stock to common stock Issuance of common stock upon closing of initial public offering Issuance of common stock upon closing of common stock purchase agreement Issuance of common stock for commitment fee Issuance of common stock to supplier Exercise of options on common stock The 1-for-7.15 reverse stock split of our common stock effected on June 17, 2015
2015-12-31
2015-12-31 858.20 未披露 定期报告 2015-12-30
2015-08-12 779.24 未披露 定期报告 2015-08-04
2015-06-26 778.81 未披露
更多>>
1.reflects the 1-for-7.15 reverse stock split of our common stock effected on June 17, 2015; 2.reflects the conversion of all outstanding shares of preferred stock into an aggregate of 3,322,676 shares of our common stock upon completion of this offering;
2015-06-24
2015-05-22 46.54 2375.72 定期报告 2015-03-31
2015-03-23 46.54 2228.72
更多>>
From December 31, 2013 to December 31, 2014 Conversion of notes payable into preferred stock subject to redemption and warrants to purchase common stock Issuance of preferred stock subject to redemption and warrants to purchase common stock, net of offering cost of $68,767 Cumulative dividends on Series B preferred stock Accretion of discount on Series C preferred stock
2014-12-31
From June 30, 2025 to September 30, 2025 Issuance of common stock for the conversion of Series A-2 preferred shares Issuance of Series A-3 preferred shares upon closing of private placement Issuance of Series B preferred shares upon closing of private placement Issuance of common stock and warrants upon closing of private placement
From March 31, 2025 to June 30, 2025 Issuance of common stock for the conversion of Series A-2 preferred shares
From December 31, 2024 to March 31, 2025 Issuance of common stock for the conversion of Series A-2 preferred shares
From December 31, 2023 to December 31, 2024 Issuance of common stock and prefunded warrants in public offering Voluntary conversion of convertible debt into common stock Redemptions of convertible debt into common stock Stock issued upon partial exercise of warrants Restricted share settlements issued to former board members Issuance of rounded shares as a result of the reverse stock split
a 1-for-50 reverse stock split of the issued shares of its common stock
Common Stock offered 14,724,058 shares by the company
From December 31, 2023 to March 31, 2024 Monthly redemptions of convertible debt into common stock
From December 31, 2022 to December 31, 2023 Redemptions of convertible debt into common stock Voluntary conversion of convertible debt into common stock
From December 31, 2022 to March 31, 2023 Voluntary conversion of convertible debt into common stock
Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split.
From June 30, 2022 to September 30, 2022 Stock issued upon exercise of warrants
From December 31, 2020 to December 31, 2021 Issuance of common stock for conversion of preferred stock Stock issued upon cash-exercise of warrants Stock issued upon net-exercise of warrants Shares issued pursuant to Securities Purchase Agreements Stock issued for professional services
From June 30, 2021 to September 30, 2021 Stock issued upon cash-exercise of warrants
From March 31, 2021 to June 30, 2021 Stock issued upon cash-exercise of warrants
From December 31, 2020 To March 31, 2021 Stock issued upon cash-exercise of warrants Stock issued upon net-exercise of warrants Stock issued for professional services
From March 31, 2020 to December 31, 2020 Issuance of common stock for conversion of preferred stock Issuance of common stock for conversion of notes payable and accrued interest Effect of reverse recapitalization Shares and warrants issued to advisor upon closing of private placement Shares and warrants issued pursuant to Securities Purchase Agreements Stock issued for professional services Warrants exercised
1.Common Stock offered by the company: 2,370,786 shares of common stock. 2.The number of shares of common stock to be outstanding immediately after this offering is based on 24,336,263 shares of common stock outstanding as of December 15, 2020.
From June 30, 2020 to September 30, 2020 Issuance of common stock for conversion of preferred stock Shares and (exercised) warrants issued pursuant to Securities Purchase Agreements
1.Common Stock offered by the company 1,717,106 shares of common stock. 2.The number of shares of common stock to be outstanding immediately after this offering is based on 19,311,731 shares of common stock outstanding as of July 31, 2020.
1.Common Stock offered by the company 1,140,570 shares of common stock. 2.The number of shares of common stock to be outstanding immediately after this offering is based on 15,689,223 shares of common stock outstanding as of July 9, 2020.
From March 31, 2020 to June 30, 2020 Issuance of common stock for conversion of preferred stock Issuance of Series Alpha preferred shares upon closing of private placement Issuance of Series Alpha preferred stock for conversion of notes payable Issuance of common stock for conversion of notes payable and accrued interest Effect of reverse recapitalization Shares and warrants issued to advisor upon closing of private placement Stock issued for professional services
1-for-25 reverse split
From December 31, 2019 to March 31, 2020 Conversion of Series B preferred shares into common stock Issuance of common shares from ATM Agreement Issuance of common shares from exercises of warrants Proceeds from issuance of shares for Aspire equity line Issuance of shares for settlement of accounts payable
From December 31, 2018 to December 31, 2019 Conversion of Series A preferred shares into common stock Conversion of Series B preferred shares into common stock Conversion of Series C preferred shares into common stock Settlement of RSUs Issuance of common shares from ATM Agreement Shareholders fractional adjustment
From June 30, 2019 to September 30, 2019 Conversion of Series B preferred shares into common stock
From December 31, 2018 to June 30, 2019 Conversion of Series B preferred shares into common stock Conversion of Series C preferred shares into common stock
from December 31, 2018 to March 31, 2019 Conversion of Series B preferred shares into common stock Conversion of Series C preferred shares into common stock
from December 31, 2017 to December 31, 2018 Issuance of Series B preferred shares upon closing of private placement Deemed dividend of preferred stock Conversion of Series A preferred shares into common stock Conversion of Series B preferred shares into common stock
Ritter Pharmaceuticals, Inc. today announced a 1-for-10 reverse split of its Common Stock, effective March 23, 2018.As a result of the reverse stock split, the number of issued and outstanding shares of Common Stock will be reduced from approximately 49,406,521 to approximately 4,940,652.
from December 31, 2016 to December 31, 2017 Conversion of series A preferred shares Issuance of shares upon follow-on offering Issuance of shares under common stock purchase agreement
From December 31, 2015 to December 09, 2016 Issuance of common stock upon closing of follow-on public offering Issuance of common stock under common stock purchase agreement Exercise of options on common stock
On October 31, 2016, the Company closed a public offering, selling 2,127,660 shares of the Company’s common stock at a price to the public of $2.35 per share, for aggregate gross proceeds to the Company of approximately $5.0 million. The Company paid to the underwriters underwriting discounts and commissions of approximately $0.4 million in connection with the offering, and approximately $0.2 million of other expenses in connection with the offering.
from December 31, 2014 to December 31, 2015 Conversion of all outstanding preferred stock subject to redemption to common stock Conversion of all outstanding preferred stock to common stock Issuance of common stock upon closing of initial public offering Issuance of common stock upon closing of common stock purchase agreement Issuance of common stock for commitment fee Issuance of common stock to supplier Exercise of options on common stock The 1-for-7.15 reverse stock split of our common stock effected on June 17, 2015
1.reflects the 1-for-7.15 reverse stock split of our common stock effected on June 17, 2015; 2.reflects the conversion of all outstanding shares of preferred stock into an aggregate of 3,322,676 shares of our common stock upon completion of this offering;
From December 31, 2013 to December 31, 2014 Conversion of notes payable into preferred stock subject to redemption and warrants to purchase common stock Issuance of preferred stock subject to redemption and warrants to purchase common stock, net of offering cost of $68,767 Cumulative dividends on Series B preferred stock Accretion of discount on Series C preferred stock
同花顺个股页面 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。

【免责声明】本产品中的行情数据及资讯信息来源于第三方，长江证券不对收集数据的版权、真实性、准确性及传输过程中发生的传送错误承担法律责任。本内容仅供参考，不作为投资决策依据，长江证券不对因据此操作产生的盈亏承担任何责任。投资有风险，入市需谨慎。